Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14

被引:148
作者
Ouillette, Peter [1 ]
Erba, Harry [1 ]
Kujawski, Lisa [1 ]
Kaminski, Mark [1 ]
Shedden, Kerby [2 ]
Malek, Sami N. [1 ]
机构
[1] Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Stat, Ann Arbor, MI 48109 USA
关键词
D O I
10.1158/0008-5472.CAN-07-3105
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chronic lymphocytic leukemia (CLL) is a biologically heterogeneous illness with a variable clinical course. Loss of chromosomal material on chromosome 13 at cytoband 13q14 is the most frequent genetic abnormality in CLL, but the molecular aberrations underlying del13q14 in CLL remain incompletely characterized. We analyzed 171 CLL cases for loss of heterozygosity and sulichromosomal copy loss on chromosome 13 in DNA from fluorescence-activated cell sorting-sorted CD19(+) cells and paired buccal cells using the Affymetrix XbaI 50k SNP array platform. The resulting high-resolution genomic maps, together with array-based measurements of expression levels of RNA in CLL cases with and without del13q14 and quantitative PCR-based expression analysis of selected genes, support the following conclusions: (a) del13q14 is heterogeneous and composed of multiple subtypes, with deletion of Rb or the miRI5a/miR16 loci serving as anatomic landmarks, respectively; (b) del13q14 type la deletions are relatively uniform in length and extend from breakpoints close to the miR15a/miR16 cluster to a newly identified telomeric breakpoint cluster at the similar to 50.2 to 50.5 Mb physical position; (c) LATS2 RNA levels are similar to 2.6-fold to 2.8-fold lower in cases with del13q14 type I that do not delete Rb, as opposed to del13q14 type 11 or all other CLL cases; (d) PHLPP RNA is absent in similar to 50% of CLL cases with del13q14; and (e) similar to 15% of CLL cases display marked reductions in miR15a/miR16 expression that are often but not invariably associated with bi-allelic miR15a/miR16 loss. These data should aid future investigations into biological differences imparted on CLL by different del13q14 subtypes.
引用
收藏
页码:1012 / 1021
页数:10
相关论文
共 50 条
[1]   A SURVEY OF MODELS FOR REPEATED ORDERED CATEGORICAL RESPONSE DATA [J].
AGRESTI, A .
STATISTICS IN MEDICINE, 1989, 8 (10) :1209-1224
[2]   A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization [J].
Aylon, Yael ;
Michael, Dan ;
Shmueli, Ayelet ;
Yabuta, Norikazu ;
Nojima, Hiroshi ;
Oren, Moshe .
GENES & DEVELOPMENT, 2006, 20 (19) :2687-2700
[3]   NCBI GEO: mining tens of millions of expression profiles - database and tools update [J].
Barrett, Tanya ;
Troup, Dennis B. ;
Wilhite, Stephen E. ;
Ledoux, Pierre ;
Rudnev, Dmitry ;
Evangelista, Carlos ;
Kim, Irene F. ;
Soboleva, Alexandra ;
Tomashevsky, Maxim ;
Edgar, Ron .
NUCLEIC ACIDS RESEARCH, 2007, 35 :D760-D765
[4]   Construction of a 780-kb PAC, BAC, and cosmid contig encompassing the minimal critical deletion involved in B cell chronic lymphocytic leukemia at 13q14.3 [J].
BouygeMoreau, I ;
Rondeau, G ;
AvetLoiseau, H ;
Andre, MT ;
Bezieau, S ;
Cherel, M ;
Saleun, S ;
Cadoret, E ;
Shaikh, T ;
DeAngelis, MM ;
Arcot, S ;
Batzer, M ;
Moisan, JP ;
Devilder, MC .
GENOMICS, 1997, 46 (02) :183-190
[5]  
Bullrich F, 2001, CANCER RES, V61, P6640
[6]   Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia [J].
Calin, GA ;
Dumitru, CD ;
Shimizu, M ;
Bichi, R ;
Zupo, S ;
Noch, E ;
Aldler, H ;
Rattan, S ;
Keating, M ;
Rai, K ;
Rassenti, L ;
Kipps, T ;
Negrini, M ;
Bullrich, F ;
Croce, CM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (24) :15524-15529
[7]   The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1 [J].
Chan, EH ;
Nousiainen, M ;
Chalamalasetty, RB ;
Schafër, A ;
Nigg, EA ;
Silljé, HHW .
ONCOGENE, 2005, 24 (12) :2076-2086
[8]   An 800-kb region of deletion at 13q14 in human prostate and other carcinomas [J].
Chen, CS ;
Frierson, HF ;
Haggerty, PF ;
Theodorescu, D ;
Gregory, CW ;
Dong, JT .
GENOMICS, 2001, 77 (03) :135-144
[9]   National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment [J].
Cheson, BD ;
Bennett, JM ;
Grever, M ;
Kay, N ;
Keating, MJ ;
OBrien, S ;
Rai, KR .
BLOOD, 1996, 87 (12) :4990-4997
[10]   Mechanisms of disease: Chronic lymphocytic leukemia [J].
Chiorazzi, N ;
Rai, KR ;
Ferrarini, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08) :804-815